SCHEMBL2898449

SCHEMBL2898449

C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(OP(=O)(O)O)C(=O)CO

nearest known ligand 0.76

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NR3C1 P04150 14/20 0.76
MMP1 P03956 11/20 0.76
CYP3A4 P08684 5/20 0.75
PGR P06401 5/20 0.75
MEN1 O00255 2/20 0.75
KMT2A Q03164 2/20 0.75
USP2 O75604 1/20 0.75
HIF1A Q16665 2/20 0.73
HSD17B10 Q99714 2/20 0.73
TSHR P16473 2/20 0.73
NFKB1 P19838 2/20 0.73
AR P10275 2/20 0.73
CYP2D6 P10635 1/20 0.73
APEX1 P27695 1/20 0.73
PMP22 Q01453 1/20 0.73
NPSR1 Q6W5P4 1/20 0.73
IKBKB O14920 1/20 0.73
CHUK O15111 1/20 0.73
ADRB2 P07550 1/20 0.73
NR3C2 P08235 1/20 0.73

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15671680 1.00 NR3C1 (0.76) NR3C1MMP1CYP3A4PGRMEN1
SCHEMBL73249 1.00 NR3C1 (0.76) NR3C1MMP1CYP3A4PGRMEN1
SCHEMBL5912759 0.99 NR3C1 (0.75) NR3C1MMP1CYP3A4PGRMEN1
Water SCHEMBL201856 0.99 NR3C1 (0.75) NR3C1MMP1CYP3A4PGRMEN1
SCHEMBL2123848 0.99 NR3C1 (0.75) NR3C1MMP1CYP3A4PGRMEN1
SCHEMBL3126388 0.99 NR3C1 (0.75) NR3C1MMP1CYP3A4PGRMEN1
SCHEMBL1301198 0.99 NR3C1 (0.75) NR3C1MMP1CYP3A4PGRMEN1
SCHEMBL3836633 0.99 NR3C1 (0.75) NR3C1MMP1CYP3A4PGRMEN1
Dexamethasone SCHEMBL3404392 0.95 HIF1A (0.82) NR3C1MMP1CYP3A4PGRMEN1
SCHEMBL11064010 0.94 NR3C1 (0.72) NR3C1MMP1CYP3A4PGRMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 668 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10080785-B2 Albumin fusion proteins NOVOZYMES BIOPHARMA DK A/S (DK) 2018-09-25 US disclosed
US-20180200346-A1 ALBUMIN FUSION PROTEINS ALBUMEDIX A/S (DK) 2018-07-19 US disclosed
US-9983196-B2 Compositions and methods for optimizing drug hydrophobicity and drug delivery to cells BIOELASTICS, INC. (US) 2018-05-29 US disclosed
US-9849162-B2 Treatment with factor VII-albumin fusion protein ALBUMEDIX A/S (DK) 2017-12-26 US disclosed
US-9821039-B2 Albumin fusion proteins ALBUMEDIX A/S (DK) 2017-11-21 US disclosed
US-9775888-B2 Treatment with factor ix-albumin fusion protein ALBUMEDIX A/S (DK) 2017-10-03 US disclosed
US-20170096472-A1 ALBUMIN FUSION PROTEINS HUMAN GENOME SCIENCES, INC. 2017-04-06 US disclosed
US-20160152687-A1 ALBUMIN FUSION PROTEINS HUMAN GENOME SCIENCES, INC. 2016-06-02 US disclosed
US-9296809-B2 Albumin fusion proteins HUMAN GENOME SCIENCES, INC. (US) 2016-03-29 US disclosed
EP-2990417-A1 ALBUMIN INSULIN FUSION PROTEIN Human Genome Sciences, Inc. (US) 2016-03-02 EP disclosed
WO-2001055367-A1 NUCLEIC ACIDS, PROTEINS, AND ANTIBODIES HUMAN GENOME SCIENCES, INC. (US) 2001-08-02 WO disclosed
WO-2001053530-A1 HUMAN PROTEIN TYROSINE PHOSPHATASE POLYNUCLEOTIDES, POLYPEPTIDES, AND ANTIBODIES HUMAN GENOME SCIENCES, INC. (US) 2001-07-26 WO disclosed
EP-0197718-B2 New medicaments for topical use FIDIA SPA (IT) 2001-07-25 EP disclosed
WO-2001051504-A1 71 HUMAN SECRETED PROTEINS HUMAN GENOME SCIENCES, INC. (US) 2001-07-19 WO disclosed
WO-2001046254-A1 TRANSFERRIN POLYNUCLEOTIDES, POLYPEPTIDES, AND ANTIBODIES HUMAN GENOME SCIENCES, INC. (US) 2001-06-28 WO disclosed
WO-2001046475-A1 TREFOIL DOMAIN-CONTAINING POLYNUCLEOTIDES, POLYPEPTIDES, AND ANTIBODIES HUMAN GENOME SCIENCES, INC. (US) 2001-06-28 WO disclosed
WO-2001046255-A1 NK CELL RECEPTOR POLYNUCLEOTIDES, POLYPEPTIDES, AND ANTIBODIES HUMAN GENOME SCIENCES, INC. (US) 2001-06-28 WO disclosed
EP-0197718-B1 New medicaments for topical use FIDIA SPA (IT) 1993-12-15 EP disclosed
EP-0555898-A2 Medicaments for non-topical use FIDIA S.p.A. (IT) 1993-08-18 EP disclosed
EP-0197718-A2 New medicaments for topical use FIDIA S.p.A. (IT) 1986-10-15 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180200346-A1 ALBUMIN FUSION PROTEINS ALB, FABP1, HDGF NR3C1 3057/4885MMP1 2327/4885CYP3A4 4376/4885
US-20160152687-A1 ALBUMIN FUSION PROTEINS ALB, FABP1, HDGF NR3C1 3057/4885MMP1 2327/4885CYP3A4 4376/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.